NHS National Framework for Transition products commencing 1 October 2024

Tender description

Project title: NHS National Framework for Transition products commencing 1 October 2024<br/>Offer reference number: CM/TNS/24/5712<br/>Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.<br/>Potential periods of call-offs under the framework agreement:<br/> <br/>CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) <br/><br/>CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) <br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England Lot 1: CM/TNS/24/5712/01 CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) Additional information: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets<br/>Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) <br/>Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) Lot 2: CM/TNS/24/5712/02 CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Additional information: CM/TNS/24/5712/02 - Imatinib<br/>Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months)